Navigation Links
Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
Date:9/14/2007

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, September 14 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today that Amir Avniel, Rosetta Genomics' CEO, will present at Maxim Group's Growth conference on Thursday, September 20, at 5:00 pm EDT at the Grand Hyatt Hotel in New York.

A live audio webcast of the presentation will be available on the "Investors" section of the company's website, http://www.RosettaGenomics.com. A replay of the presentation will be available for 30 days after the conference.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases. For more information please visit: http://www.rosett
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Genomics researcher Hood joins NimbleGen board
3. GE Healthcare partners with genomics institute
4. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. BxVideo designs Web hosting service for Sonic Foundry media presentations
9. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
10. ArrayScript RT: Maximize Yields of Full-length cDNA
11. Maximize Viral RNA Yield from Biological Fluid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... SEABROOK, N.H. , May 22, 2013 /PRNewswire/ ... of the Year 2013" by Business NH Magazine.  ... recognized Granite State organizations that distinguish themselves with ... are very proud to receive this honor," said ... Superior Controls.  "As with any recognition, this award ...
(Date:5/22/2013)... Toronto, Ontario (PRWEB) May 22, 2013 ... of advanced sound therapy for tinnitus treatment. AudioNotch ... Destination Hearing . With clinic locations in both ... trusted provider of audiology and hearing services. AudioNotch's ... Zabell locations. , Upon entering a Destination Hearing ...
(Date:5/22/2013)... Envera announced today that Michael McErlean ... McErlean has an extensive background in cell production and ... career. , Mike Matheny, President and Owner ... Mike join our team”. “Mike’s background is perfectly suited ... and downstream processing equipment”, added Matheny. “Mike’s hands ...
(Date:5/21/2013)... , May 22, 2013 ... drug-only formulation of glycopyrronium bromide designed using Prosonix, particle ... company developing a portfolio of inhaled Respiratory Medicines ... study with PSX1002 that will assess its effect on ... doses in patients with moderate to severe chronic obstructive ...
Breaking Biology Technology:Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... Mass.,  Feb. 4, 2011 The ALS ... elected Anil Godhwani, a successful Silicon Valley entrepreneur, to ... "nonprofit biotechnology" organization with a mission to discover and ... sclerosis (ALS, Lou Gehrig,s Disease). (Logo: ...
... Pharmacyclics, Inc. (Nasdaq: PCYC ) today ... second quarter that ended December 31, 2010.Recent Developments & ... Btk Inhibitor PCI-32765 in B-cell malignanciesPharmacyclics has designed a ... lymphocytic leukemia and diffuse large B-cell lymphoma to inform ...
... Boston College has been awarded a $1 million grant ... of university researchers developing a new microscope that uses ... and macroscopic matter with significantly improved clarity. The ... new class of microscopes known as "superlenses," which function ...
Cached Biology Technology:ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 3Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 4Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 5Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 6Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 7Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 8Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 9Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope 2
(Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... considered in the management of natural resources, and ... help them recognize and respond to the relationships ... , Place-Based Conservation: Perspectives from the Social ... Northwest Research Station,s Linda Kruger, can help managers ... is published by Springer Verlag and is available ...
Breaking Biology News(10 mins):Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Small but speedy: Short plants live in the evolutionary fast lane 2
... in the Earth and its atmosphere, such as melting polar ... of global climate change. But changes in climate can wreak ... habitat for plant and animal species. In a series of ... Meeting, climate change scientists will discuss how temperature-induced habitat loss ...
... into an epidemic, reflected in soaring rates of type ... elevated cholesterol. What hasn,t been as clear is ... a pediatric research program on Friday suggested obesity prevention ... children reach a "tipping point" in a progression that ...
... a genetically induced lack of filaggrin, a key protein ... the origin of allergies. In a large study on ... Mnchen and the Technische Universitt Mnchen found that about ... filaggrin gene, which raise the risk to develop atopic ...
Cached Biology News:Climate change and species distributions 2Climate change and species distributions 32 years old -- a childhood obesity tipping point? 2When our protective armor shows weakness 2
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
EDG-6 (1)...
Complexin-1/2 (FL-134)...
Biology Products: